Effect of sulfinpyrazone on platelet survival time in patients with transient cerebral ischemic attacks

Peter Steele, James Carroll, Dale Overfield, Edward Genton

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Platelet suppressant drugs have been suggested as beneficial for patients with transient cerebral ischemic attacks and these drugs have been shown to lengthen shortened platelet survival time. In the present study platelet survival time (autologous labeling with 10Chromium) was measured in 25 patients with transient cerebral ischemia involving a carotid distribution. Platelet survival was shortened in all patients (2.5 ± 0.10 days; AVE t 1/2 ± Sem; Normal 3.7 ± 0.04 days P < 0.001). Sulfinpyrazone increased platelet survival in 9 of 19 (47%) of patients (2.4 ± 0.10 to 2.8 ± 0.16 days; P < 0.01). Of the 19 treated with sulfinpyrazone, 10 had a marked reduction in the frequency of transient ischemic episodes and an increased in platelet survival (2.6 ± 0.16 to 3.1 ± 0.22 days; P < 0.01) was observed in all patients. Three patients had no benefit from sulfinpyrazone and alteration of platelet survival did not occur. Results suggest that platelet survival is shortened in patients with transient cerebral ischemia, that sulfinpyrazone increases platelet survival and may decrease the frequency of ischemic episodes, and that there may be a relationship between clinical benefit and alteration of platelet survival time.

Original languageEnglish (US)
Pages (from-to)396-398
Number of pages3
JournalStroke
Volume8
Issue number3
DOIs
StatePublished - Jan 1 1977
Externally publishedYes

Fingerprint

Sulfinpyrazone
Transient Ischemic Attack
Blood Platelets
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Effect of sulfinpyrazone on platelet survival time in patients with transient cerebral ischemic attacks. / Steele, Peter; Carroll, James; Overfield, Dale; Genton, Edward.

In: Stroke, Vol. 8, No. 3, 01.01.1977, p. 396-398.

Research output: Contribution to journalArticle

Steele, Peter ; Carroll, James ; Overfield, Dale ; Genton, Edward. / Effect of sulfinpyrazone on platelet survival time in patients with transient cerebral ischemic attacks. In: Stroke. 1977 ; Vol. 8, No. 3. pp. 396-398.
@article{f08d6017a66640bbabbffa451f6f2895,
title = "Effect of sulfinpyrazone on platelet survival time in patients with transient cerebral ischemic attacks",
abstract = "Platelet suppressant drugs have been suggested as beneficial for patients with transient cerebral ischemic attacks and these drugs have been shown to lengthen shortened platelet survival time. In the present study platelet survival time (autologous labeling with 10Chromium) was measured in 25 patients with transient cerebral ischemia involving a carotid distribution. Platelet survival was shortened in all patients (2.5 ± 0.10 days; AVE t 1/2 ± Sem; Normal 3.7 ± 0.04 days P < 0.001). Sulfinpyrazone increased platelet survival in 9 of 19 (47{\%}) of patients (2.4 ± 0.10 to 2.8 ± 0.16 days; P < 0.01). Of the 19 treated with sulfinpyrazone, 10 had a marked reduction in the frequency of transient ischemic episodes and an increased in platelet survival (2.6 ± 0.16 to 3.1 ± 0.22 days; P < 0.01) was observed in all patients. Three patients had no benefit from sulfinpyrazone and alteration of platelet survival did not occur. Results suggest that platelet survival is shortened in patients with transient cerebral ischemia, that sulfinpyrazone increases platelet survival and may decrease the frequency of ischemic episodes, and that there may be a relationship between clinical benefit and alteration of platelet survival time.",
author = "Peter Steele and James Carroll and Dale Overfield and Edward Genton",
year = "1977",
month = "1",
day = "1",
doi = "10.1161/01.STR.8.3.396",
language = "English (US)",
volume = "8",
pages = "396--398",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effect of sulfinpyrazone on platelet survival time in patients with transient cerebral ischemic attacks

AU - Steele, Peter

AU - Carroll, James

AU - Overfield, Dale

AU - Genton, Edward

PY - 1977/1/1

Y1 - 1977/1/1

N2 - Platelet suppressant drugs have been suggested as beneficial for patients with transient cerebral ischemic attacks and these drugs have been shown to lengthen shortened platelet survival time. In the present study platelet survival time (autologous labeling with 10Chromium) was measured in 25 patients with transient cerebral ischemia involving a carotid distribution. Platelet survival was shortened in all patients (2.5 ± 0.10 days; AVE t 1/2 ± Sem; Normal 3.7 ± 0.04 days P < 0.001). Sulfinpyrazone increased platelet survival in 9 of 19 (47%) of patients (2.4 ± 0.10 to 2.8 ± 0.16 days; P < 0.01). Of the 19 treated with sulfinpyrazone, 10 had a marked reduction in the frequency of transient ischemic episodes and an increased in platelet survival (2.6 ± 0.16 to 3.1 ± 0.22 days; P < 0.01) was observed in all patients. Three patients had no benefit from sulfinpyrazone and alteration of platelet survival did not occur. Results suggest that platelet survival is shortened in patients with transient cerebral ischemia, that sulfinpyrazone increases platelet survival and may decrease the frequency of ischemic episodes, and that there may be a relationship between clinical benefit and alteration of platelet survival time.

AB - Platelet suppressant drugs have been suggested as beneficial for patients with transient cerebral ischemic attacks and these drugs have been shown to lengthen shortened platelet survival time. In the present study platelet survival time (autologous labeling with 10Chromium) was measured in 25 patients with transient cerebral ischemia involving a carotid distribution. Platelet survival was shortened in all patients (2.5 ± 0.10 days; AVE t 1/2 ± Sem; Normal 3.7 ± 0.04 days P < 0.001). Sulfinpyrazone increased platelet survival in 9 of 19 (47%) of patients (2.4 ± 0.10 to 2.8 ± 0.16 days; P < 0.01). Of the 19 treated with sulfinpyrazone, 10 had a marked reduction in the frequency of transient ischemic episodes and an increased in platelet survival (2.6 ± 0.16 to 3.1 ± 0.22 days; P < 0.01) was observed in all patients. Three patients had no benefit from sulfinpyrazone and alteration of platelet survival did not occur. Results suggest that platelet survival is shortened in patients with transient cerebral ischemia, that sulfinpyrazone increases platelet survival and may decrease the frequency of ischemic episodes, and that there may be a relationship between clinical benefit and alteration of platelet survival time.

UR - http://www.scopus.com/inward/record.url?scp=0017737116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017737116&partnerID=8YFLogxK

U2 - 10.1161/01.STR.8.3.396

DO - 10.1161/01.STR.8.3.396

M3 - Article

VL - 8

SP - 396

EP - 398

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 3

ER -